Other substances

RBD nanoparticle vaccine

An experimental COVID-19 vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

2
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

RBD nanoparticle vaccine is composed of Helicobacter pylori non-haem ferritin self-assembled nanoparticles, each with 24 copies of covalently conjugated receptor binding domains (of SARS-CoV-2 Spike protein) (Ma et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Spike protein Biophysical assay Protein factor Animal model In vitro Mixed substance 		in vitro biophysical assay; hACE2-HeLa cells; BALB/c mice; hACE2-mice; rhesus macaques 22.55

The nanoparticles bound to ACE2 with similar affinity as RBD monomers in vitro. The elicited murine antibodies significantly inhibited RBD-ACE2 interaction. The nanoparticle vaccine produced stronger anti-RBD humoral IgG response in BALB/c mice than in the case of monomeric RBD vaccination. The antibody titres peaked as early as two weeks post priming. The nanoparticles elicited strong neutralizing antibody responses (against both SARS-CoV-2 live- and pseudoviruses). Strong T and B cell responses were detected in immunized BALB/c mice. The observed stronger responses to nanoparticles compared to the corresponding monomeric antigens might have been the result of stronger capture by dendritic cells and macrophages. The nanoparticles protected hACE2-mice from SARS-CoV-2 infection without signs of antibody-dependent enhancement and exerted robust immunogenicity in rhesus macaques.

 Nov/25/2020
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
Spike protein Protein factor Animal model In vitro Mixed substance 		HEK293T cells; COVID-19 convalescent patient sera; immunized rhesus macaques' sera; SARS-CoV-2 variant Spike-pseudotyped virus 8.48

The sera from RBD nanoparticle-vaccinated rhesus macaques neutralized SARS-CoV-2 Spike-pseudotyped virus specific for D614G (SYSU-IHV), B.1.1.7, and 501Y.V2 emergent strains, but the neutralization capacity was significantly lower for the 501Y.V2 (“South Africa”) strain.

 Feb/12/2021
Export (.csv)